Key Takeaway: Zoetis Inc. has launched Lenivia® (izenivetmab injection) in Canada and the EU, a new long-acting monoclonal antibody therapy for osteoarthritis pain management. This innovative treatment can provide relief for up to three months with a single subcutaneous injection. The launch is supported by a decade of research and a successful nine-month European field study.
Price reaction · baseline $74.07 (2026-07-14 close) · hit pre-market · clean, no other ZTS news in the window
day 0 close
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Launch of Lenivia provides a new treatment option for osteoarthritis pain management.
The therapy offers long-lasting effects with a single injection.
Backed by extensive research and a pivotal nine-month study.
Full Press Release Details
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in pain in a pivotal nine-month European field study
Frequently Asked Questions
What is Lenivia®?
Lenivia® (izenivetmab injection) is a long-acting monoclonal antibody therapy for osteoarthritis pain management.
How long does Lenivia® provide pain relief?
Lenivia® offers pain relief for up to three months with a single subcutaneous injection.
In which regions has Lenivia® been launched?
Lenivia® has been launched in Canada and the European Union member states.
What supports the efficacy of Lenivia®?
The efficacy of Lenivia® is backed by a decade of research and a pivotal nine-month European field study.